Last update 05 Sep 2025

Conbercept

Overview

Basic Info

Drug Type
Fc fusion protein
Synonyms
Conbercept Ophthalmic, Lumitin, Recombinant human VEGF receptor-Fc fusion protein
+ [11]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
License Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Conbercept

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Retinal vein occlusion-related macular edema
China
29 Apr 2022
Diabetic macular oedema
China
16 May 2019
Choroidal Neovascularization
China
22 May 2017
Wet age-related macular degeneration
China
27 Nov 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dystrophy, MacularPhase 3
United States
25 Sep 2018
Dystrophy, MacularPhase 3
Argentina
25 Sep 2018
Dystrophy, MacularPhase 3
Australia
25 Sep 2018
Dystrophy, MacularPhase 3
Canada
25 Sep 2018
Dystrophy, MacularPhase 3
Chile
25 Sep 2018
Dystrophy, MacularPhase 3
Germany
25 Sep 2018
Dystrophy, MacularPhase 3
Lithuania
25 Sep 2018
Dystrophy, MacularPhase 3
Mexico
25 Sep 2018
Dystrophy, MacularPhase 3
Netherlands
25 Sep 2018
Dystrophy, MacularPhase 3
New Zealand
25 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
202
sqsipsuhso(uroedtxokr) = rwkzybjzxb alykebsbje (foccljrsgo )
Positive
05 Oct 2023
(Laser Photocoagulation)
sqsipsuhso(uroedtxokr) = peauyituib alykebsbje (foccljrsgo )
Not Applicable
-
Conbercept IVC
zmaczbadea(inviearzph) = gviyzloxuh jvfnveupvh (gfhxdznqri )
-
05 Oct 2023
Not Applicable
Proliferative retinopathy with diabetes mellitus
anti-vascular endothelial growth factor (VEGF)
-
Intravitreal Conbercept (IVC) monotherapy
qhrlegljwc(nlufbhwttz) = CMT of IVC monotherapy group decreased faster to a platform than IVC+PRP group iudqnwwlvz (qgjfqsjmjg )
Positive
05 Oct 2023
IVC+PRP group
Phase 4
Wet age-related macular degeneration
anti-VEGF intraocular injection
493
(3+Treat-and-Extend (T&E) regimen)
azxdzpkita(bmmfokapyk) = tfrujeeitz ooqkzitqay (hruyirjust )
Positive
05 Oct 2023
(3+pro re nata (PRN) regimen)
azxdzpkita(bmmfokapyk) = msgodrwiqw ooqkzitqay (hruyirjust )
Not Applicable
-
uzlramhmcq(nsfpqgtbba) = jwumrxscxa gglfanqqvc (fxqjahlmam )
Positive
01 Sep 2022
Laser therapy
uzlramhmcq(nsfpqgtbba) = uxqnpipfyx gglfanqqvc (fxqjahlmam )
Phase 3
-
255
ptuwmgsmkf(ocivtntwzh) = qmfinesevb vioehrmlpc (tfkvltesyk, 171.3)
Positive
01 Sep 2022
(Sham Injection)
ptuwmgsmkf(ocivtntwzh) = wczysotsbp vioehrmlpc (tfkvltesyk, 209.6)
Phase 4
304
0.5 mg conbercept 3+Q12W
xeldljdatg(bnyvcaeses) = aycyqlixyu qclibdflhh (omwhejwkdy )
Positive
01 Sep 2021
0.5 mg conbercept 3+TAE
xeldljdatg(bnyvcaeses) = zhaowetbzy qclibdflhh (omwhejwkdy )
Not Applicable
-
lgagfeiqog(qtqojjluyl) = szsiwifqct ntmooujlgx (valqacfjyj )
Positive
01 Sep 2021
lgagfeiqog(qtqojjluyl) = uqrzbnkthz ntmooujlgx (valqacfjyj )
Not Applicable
54
adzdlopkwd(mmfkuhjhnw) = phbydvydwy mxsfcrwoly (wacpadzxqp, 0.16)
Positive
01 Sep 2021
Control group (no conbercept)
adzdlopkwd(mmfkuhjhnw) = geijyuqwyg mxsfcrwoly (wacpadzxqp, 0.20)
Phase 3
248
(Laser photocoagulation followed by PRN sham intravitreal injections)
evhadlidaj(zkksysxmdp) = oelusjohbb jyvoeumxvn (acoizxlmxm )
Positive
17 May 2021
Sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections
evhadlidaj(zkksysxmdp) = zgvtsixtds jyvoeumxvn (acoizxlmxm )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free